FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3080956141> ?p ?o ?g. }

• W3080956141 endingPage "2040" @default.
• W3080956141 startingPage "2026" @default.
• W3080956141 abstract "Objective To assess the efficacy of erenumab at the ≥50%, ≥75%, and 100% reduction in monthly migraine days (MMD) response thresholds, using data from the 6‐month double‐blind treatment phase (DBTP) of the Study to Evaluate the Efficacy and Safety of Erenumab in Migraine Prevention (STRIVE) pivotal clinical trial. Methods Enrolled patients with episodic migraine (EM; ≥4 MMD and <15 monthly headache days) were randomized (1:1:1) to erenumab 70 mg (n = 312), erenumab 140 mg (n = 318), or placebo (n = 316) once monthly. We determined the proportions of patients with ≥50%, ≥75% and 100% reduction in MMD over the last 3 months of the STRIVE DBTP (months 4 through 6) and conducted post hoc analyses to contextualize the treatment benefit in patient subgroups achieving, and not achieving, these response thresholds. Outcome measures included changes in MMD, acute migraine‐specific medication days (MSMD), and patient‐reported outcomes. Results The proportions of patients with a reduction in MMD from baseline were greater for erenumab than for placebo at all response thresholds. As previously reported for the ≥50% response threshold, 135/312 (43.3%) of patients on erenumab 70 mg and 159/318 (50.0%) on erenumab 140 mg responded, vs 84/316 (26.6%) for placebo. At months 4 through 6, 65/312 (20.8%) and 70/318 (22.0%) of those on erenumab 70 mg and erenumab 140 mg, respectively, achieved ≥75% reductions vs 25/316 (7.9%) on placebo. A reduction of 100% response, which required no migraine days over 3 consecutive months based on observed data, was achieved by 10/312 (3.2%) of patients treated with erenumab 70 mg and 16/318 (5.0%) for erenumab 140 mg, vs 9/316 (2.8%) for placebo. At all response thresholds, responders achieved numerically greater reductions in mean MMD and MSMD, and greater improvements in disability than did the overall population; importantly, these remarkable responses were noted early. Meanwhile, 60/312 (19.2%) and 53/318 (16.7%) patients on erenumab 70 and 140 mg, respectively, had no reduction in MMD from baseline in months 4 through 6, compared with 104/316 (32.9%) patients on placebo. Conclusions The responses at the ≥50%, ≥75%, and 100% thresholds provide context for establishing realistic patient and physician expectations regarding the magnitude of treatment benefit that may be achieved by patients with EM responding to erenumab (STRIVE, NCT02456740)." @default.
• W3080956141 created "2020-09-01" @default.
• W3080956141 creator A5002736298 @default.
• W3080956141 creator A5005967479 @default.
• W3080956141 creator A5009860624 @default.
• W3080956141 creator A5045656538 @default.
• W3080956141 creator A5051082265 @default.
• W3080956141 creator A5052274720 @default.
• W3080956141 creator A5057030908 @default.
• W3080956141 creator A5057290642 @default.
• W3080956141 creator A5091278189 @default.
• W3080956141 creator A5091415499 @default.
• W3080956141 date "2020-08-26" @default.
• W3080956141 modified "2023-10-18" @default.
• W3080956141 title "The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response" @default.
• W3080956141 cites W2047041272 @default.
• W3080956141 cites W204766049 @default.
• W3080956141 cites W2073160193 @default.
• W3080956141 cites W2122311626 @default.
• W3080956141 cites W2268603990 @default.
• W3080956141 cites W2283260670 @default.
• W3080956141 cites W2397083400 @default.
• W3080956141 cites W2586533881 @default.
• W3080956141 cites W2594986299 @default.
• W3080956141 cites W2608751463 @default.
• W3080956141 cites W2748627085 @default.
• W3080956141 cites W2750798923 @default.
• W3080956141 cites W2751884637 @default.
• W3080956141 cites W2763655322 @default.
• W3080956141 cites W2769724041 @default.
• W3080956141 cites W2770965214 @default.
• W3080956141 cites W2789321599 @default.
• W3080956141 cites W2792811290 @default.
• W3080956141 cites W2793051137 @default.
• W3080956141 cites W2885852770 @default.
• W3080956141 cites W2893863004 @default.
• W3080956141 cites W2898072840 @default.
• W3080956141 cites W2980838981 @default.
• W3080956141 cites W2996109380 @default.
• W3080956141 cites W4244823958 @default.
• W3080956141 doi "https://doi.org/10.1111/head.13929" @default.
• W3080956141 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7590156" @default.
• W3080956141 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32851644" @default.
• W3080956141 hasPublicationYear "2020" @default.
• W3080956141 type Work @default.
• W3080956141 sameAs 3080956141 @default.
• W3080956141 citedByCount "11" @default.
• W3080956141 countsByYear W30809561412020 @default.
• W3080956141 countsByYear W30809561412021 @default.
• W3080956141 countsByYear W30809561412022 @default.
• W3080956141 countsByYear W30809561412023 @default.
• W3080956141 crossrefType "journal-article" @default.
• W3080956141 hasAuthorship W3080956141A5002736298 @default.
• W3080956141 hasAuthorship W3080956141A5005967479 @default.
• W3080956141 hasAuthorship W3080956141A5009860624 @default.
• W3080956141 hasAuthorship W3080956141A5045656538 @default.
• W3080956141 hasAuthorship W3080956141A5051082265 @default.
• W3080956141 hasAuthorship W3080956141A5052274720 @default.
• W3080956141 hasAuthorship W3080956141A5057030908 @default.
• W3080956141 hasAuthorship W3080956141A5057290642 @default.
• W3080956141 hasAuthorship W3080956141A5091278189 @default.
• W3080956141 hasAuthorship W3080956141A5091415499 @default.
• W3080956141 hasBestOaLocation W30809561411 @default.
• W3080956141 hasConcept C126322002 @default.
• W3080956141 hasConcept C142724271 @default.
• W3080956141 hasConcept C187960798 @default.
• W3080956141 hasConcept C204787440 @default.
• W3080956141 hasConcept C27081682 @default.
• W3080956141 hasConcept C2778541695 @default.
• W3080956141 hasConcept C44249647 @default.
• W3080956141 hasConcept C535046627 @default.
• W3080956141 hasConcept C67761136 @default.
• W3080956141 hasConcept C71924100 @default.
• W3080956141 hasConceptScore W3080956141C126322002 @default.
• W3080956141 hasConceptScore W3080956141C142724271 @default.
• W3080956141 hasConceptScore W3080956141C187960798 @default.
• W3080956141 hasConceptScore W3080956141C204787440 @default.
• W3080956141 hasConceptScore W3080956141C27081682 @default.
• W3080956141 hasConceptScore W3080956141C2778541695 @default.
• W3080956141 hasConceptScore W3080956141C44249647 @default.
• W3080956141 hasConceptScore W3080956141C535046627 @default.
• W3080956141 hasConceptScore W3080956141C67761136 @default.
• W3080956141 hasConceptScore W3080956141C71924100 @default.
• W3080956141 hasFunder F4320307105 @default.
• W3080956141 hasIssue "9" @default.
• W3080956141 hasLocation W30809561411 @default.
• W3080956141 hasLocation W30809561412 @default.
• W3080956141 hasLocation W30809561413 @default.
• W3080956141 hasOpenAccess W3080956141 @default.
• W3080956141 hasPrimaryLocation W30809561411 @default.
• W3080956141 hasRelatedWork W2075727278 @default.
• W3080956141 hasRelatedWork W2880621648 @default.
• W3080956141 hasRelatedWork W2936672162 @default.
• W3080956141 hasRelatedWork W3015996685 @default.
• W3080956141 hasRelatedWork W3094653551 @default.
• W3080956141 hasRelatedWork W3162538154 @default.
• W3080956141 hasRelatedWork W3213340312 @default.
• W3080956141 hasRelatedWork W4283389985 @default.

• next